.webp&w=384&q=75){kind=logo}
Loading, please wait...
Loading, please wait...
Researchers recently identified XYD270 as a highly potent and selective BRD9 PROTAC cancer therapy for treating aggressive malignancies. This novel degrader specifically targets bromodomain-containing protein 9 (BRD9). Moreover, it acts as a crucial component of the non-canonical BAF (ncBAF) complex. By utilizing proteolysis-targeting chimera (PROTAC) technology, XYD270 effectively hijacks the cellular machinery. Consequently, this approach eliminates oncogenic proteins. This molecule offers a significant advantage over traditional small-molecule inhibitors in treating synovial sarcoma (SS) and acute myeloid leukemia (AML).
In various laboratory models, XYD270 demonstrated exceptional degradation activity. For instance, the molecule achieved a half-maximal degradation concentration (DC50) of 0.082 nM in HS-SY-II cells. Additionally, it showed robust antiproliferative effects in MV4;11 cells with an IC50 of 50 nM. Furthermore, in vivo studies confirmed these results. Specifically, once-daily oral administration of 10 mg/kg in an MV4;11 xenograft model resulted in 54% tumor growth inhibition (TGI). Therefore, these findings suggest that BRD9 degradation is a viable strategy for precision oncology.
The design of XYD270 involved the optimization of diverse cereblon-binding ligands to ensure high selectivity. Consequently, the molecule minimizes off-target effects while maximizing the degradation of the ncBAF complex. Because it is orally bioavailable, XYD270 presents a more convenient treatment option for future clinical applications. Scientists believe that this breakthrough will pave the way for new therapies targeting previously undruggable epigenetic factors.
XYD270 functions as a PROTAC, recruiting an E3 ubiquitin ligase to the BRD9 protein. This process facilitates the ubiquitination and subsequent degradation of BRD9 by the proteasome system within the cell.
Synovial sarcoma is characterized by a specific fusion oncoprotein that makes the cancer highly dependent on the ncBAF complex. Targeting BRD9 with a BRD9 PROTAC cancer therapy disrupts this essential survival mechanism.
Disclaimer: This content is for informational and educational purposes only and does not constitute medical advice, diagnosis, or treatment. Always seek the advice of a qualified healthcare provider with any questions regarding a medical condition. Refer to the latest local and national guidelines for clinical practice.
References
Huang Y et al. Discovery of XYD270 as a Potent, Selective, and Orally Efficacious BRD9 PROTAC for Cancer Therapy. J Med Chem. 2026 Mar 04. doi: 10.1021/acs.jmedchem.5c02858. PMID: 41782172.
National Institutes of Health (NIH). Targeted Protein Degradation in Cancer: PROTACs, New Targets, and Clinical Mechanisms. Published February 2026. Accessed March 2026.
Read summarized clinical updates, watch expert medical content, and earn CME certifications right from your smartphone.
Open your smartphone camera to scan and install.
XYD270 is a novel, orally bioavailable BRD9 PROTAC demonstrating significant potency in treating synovial sarcoma and acute myeloid leukemia in preclinical ...
7 months ago
Explore why official drug package inserts fail to reflect modern evidence for clozapine prescribing. Learn how legal standards of care, case law, slow titration, and vital adverse event monitoring empower clinicians to prioritize evidence-based medical practice over outdated manufacturer labeling.
Today
Occult maternal malignancy accounts for 3.82% of persistent unreportable NIPT results with genomic noise. Multiple chromosomal aberrations, notably on chromosome 18, warrant thorough oncological evaluation and whole-body MRI to ensure timely maternal diagnosis while preserving fetal care.
Today
This article reviews the forensic and clinical complexities of acute myocarditis arising on left ventricular hypertrophy in children, highlighting early diagnostic red flags and multidisciplinary postmortem autopsy protocols.
Today
A randomized controlled trial demonstrates that an eight-week dual-task training intervention significantly improves static and dynamic postural control over standard balance exercises in individuals with chronic ankle instability, addressing critical neurocognitive deficits during athletic and daily activities.
Today
A retrospective cohort study of 7,716 ICU patients from the MIMIC-IV database demonstrates that Gradient Boosting Decision Trees significantly outperform traditional SOFA scores in predicting in-hospital mortality among patients with sepsis and diabetes, with SHAP analysis providing clinical interpretability.
Today
